TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Fluticasone dose reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: reflex lacrimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tonometry completion time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: patient preference
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: erythropoietin concentrations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Total effective rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of serum LH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of serum FSH
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Levels of serum E2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Death or any hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: Death or HF hospitalization
Endpoint domain: Mortality/survival
Primary endpoint: weekly dog walking minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: social anxiety scales
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: general anxiety and depression levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: microbiological success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Epithelial healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: General behavior during AVD sessions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Satisfaction with AVD eyeglasses
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of RCTs in JIA
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Tumor thickness reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Complete index HSIL clearance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete or partial clearance of HSIL
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: long-term retention of PC/PSA
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Rates of physical or verbal violence
Endpoint domain: Adverse events/effects
Primary endpoint: reduced alcohol consumption
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Major molecular response (MMR) at 18 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Complete cytogenetic response (CCyR) at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraventricular dyssynchrony
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Aortic velocity time integral
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Hemoglobin (Hb) levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Cumulative morphine consumption at 24 h
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: UPDRS-III scores off-medication on-stimulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PDQ-39 summary index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Thyroid Stimulating Hormone (TSH)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Thyroglobulin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: functional health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: sleep-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Incidence of postoperative cognitive dysfunction (POCD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time to discharge
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Survival related to increased BMI
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence related to increased BMI
Endpoint domain: Mortality/survival
Primary endpoint: initial thrombus burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: corrected TIMI frame count (cTFC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: open infarct related vessel (TIMI 2 or 3 flow)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Dentin hypersensitivity reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Inhibition of Platelet Aggregation (IPA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: self-rated health improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Subjective report of pain on the Visual Analog Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daytime systolic blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in brachial artery FMD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Complete and partial responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Stable disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Urinary retention frequency
Endpoint domain: Adverse events/effects
Primary endpoint: Morphine use during PCA therapy
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: > 50% pain relief after CRFA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Visual Analog Scale points decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of > 50% pain relief
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Performance Category (CPC) 1 or 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Modified Rankin Scale (MRS) of slight disability or better
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: M/I (insulin‐stimulated whole‐body glucose disposal)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: time to first trigger of PCA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean total duration of rotaviral diarrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: VAS score change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Speed of change over time on the Panic Disorder Severity Scale (PDSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 40% PDSS reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: time to major depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: incidence of major depressive episodes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean decrease in depressive symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Supervision satisfaction
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Perceived supervision effectiveness
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Burnout levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Hospital readmission costs
Endpoint domain: Resource use
Primary endpoint: BC concentration in buccal mucosal cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: uneventful resolution
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maternal plasma triglycerides
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Severe Retinopathy of Prematurity (ROP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity for detecting WMA by 3D DSE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Residual symptoms
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Relapse at 6-month follow-up
Endpoint domain: Mortality/survival
Primary endpoint: Improved functional status
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: daily rhinoconjunctivitis symptom score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily rescue medication score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: daily medication cost
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Total cholesterol and triglyceride levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: NAFLD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Intraexaminer reliability for T(x) distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraexaminer reliability for vertebra(apex)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraexaminer reliability for Rz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraexaminer reliability for CDA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in weekly frequency of cluster headache attacks
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of patients with at least 50% reduction in headache frequency at week 3
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Declarative memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Working memory improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Personal Accomplishment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prolongation of SP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Effect of iTBS and cTBS on motor cortex
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Stable disease ≥4 months/Partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rates of pregnancy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Rates of term delivery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Fatty acid composition of peripheral blood mononuclear cell phospholipids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Completion rate of the trial
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: MC-SF-MPQ score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PUQE score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pulse Rate (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in SOWS scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MP-score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: determination of the appropriate therapy from the ICD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: alteration of the assigned treatment because of its harmful effects and/or frequent ICD therapies
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of significant complications
Endpoint domain: Adverse events/effects
Primary endpoint: CHD events
Endpoint domain: Mortality/survival
Primary endpoint: GAD-symptomatology
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: full remission at post-treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seizure Control
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: End-of-day comfort ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: End-of-day dryness ratings
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of CIEs and SICS
Endpoint domain: Adverse events/effects
Primary endpoint: Suppression of MSA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Target lesion failure (TLF)
Endpoint domain: Adverse events/effects
Primary endpoint: Target vessel failure (TVF)
Endpoint domain: Adverse events/effects
Primary endpoint: efficiency of NGF treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Activation frequency (Ac.F.)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Osteoid surface (OS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Serum amino terminal propeptide of type I procollagen (PINP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: acute diarrhea incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Rate of cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Positivity rate of TTT protocol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reproducibility of test results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TIMI 3 flow at 90 minutes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Stool weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Immediate stone-free rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Control of nausea
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: efficacy rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of lesion removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Improvement on the conduct problem subscale score of the Nisonger Child Behavior Rating Form
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post-meal plasma cortisol levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: self-reported asthma control
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: asthma knowledge
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: self-management skills
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: reduction in disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Forced expiratory volume in 1 s (FEV(1)) decline
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Expression of pin1 mRNA in NSCLC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Expression of pin1 mRNA post-operation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: GH response to exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Plasma lactate levels after exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Visit-to-visit systolic BP variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Visit-to-visit pulse pressure variability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: change in pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: home exercise adherence
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Improvement in 3D angles of C2, C3, and C4
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 24-hour urine protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: serum levels of uric acid
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: urinary excretion of sodium
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: incidence of grade II and higher pressure ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Acute-phase ROP status correspondence between fellow eyes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Scaling scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total daily energy intake (EI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean average low back pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: back-related disability
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Pain scores after vaccination
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent clearance of r-hLIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent volume of distribution of r-hLIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of absorption phase of r-hLIF
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plasma Ang II level decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Improvement in endothelial function (FMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Characteristic strength (σ(0))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in plasma concentration of prothrombin fragments 1 plus 2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Reduction in antithrombin, protein C, and free protein S levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Increase in D‐dimers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Bone Mineral Density (BMD) at midshaft of the ulna
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Change in CSDD score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean decrease in tardive dyskinesia subscale score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported practice score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaginal delivery within 12 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lower-segment cesarean delivery rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Amount of high calorie snack food consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic exposure to armodafinil (AUC(τ) and C(max))
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rates for resting function
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recovery rates for CR
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: odds of epileptiform EEGs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reduction in the odds of PONV
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the odds of vomiting
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elevation of serum CK levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: RHI (Reactive Hyperemia Index)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Decline in intraoperative PTH level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Normal serum calcium levels postoperatively
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adherence measured by returned medication weight
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: successful IV cannulation on first attempt
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary excretion of KIM-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Serum creatinine elevation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: state anxiety levels
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing